Morningside Pharmaceuticals Ltd has announced the company is growing its board of directors by creating two new roles as part of the business’ ambitious growth plans for the future.
The new Chief Operating Officer (COO) and Chief Financial Officer (CFO) report directly into the Chief Executive and will become members of the company’s board and governance committees.
Dr Nik Kotecha OBE, Chief Executive of Morningside Pharmaceuticals, said: “I am very pleased to welcome both Cliff and Monica onto the Board of Directors.
“We are beginning an exciting new chapter at Morningside, where the skills, experience and expertise of both individuals will be critical to delivering our ambitious future plans.”
The business is a leading manufacturer and supplier of quality generic and branded medicines to the UK and international export markets. It includes twice daily deliveries to the NHS, hospitals and pharmacies in the UK; and supplying vital medicines and healthcare products to charities, Non-Governmental Organisations (NGOs) and International Aid Agencies world-wide.
Morningside’s growth plans include launching new generic medicines from its research and development (R&D) pipeline, registering products in international export markets and further growing branded and generic medicine market share and ranges in the UK.
Morningside’s new executives
Monica Huang has been promoted into the role of Chief Operating Officer (COO). Throughout her career, Monica has worked tirelessly behind the scenes, and guided by Morningside’s Chief Executive Dr Nik Kotecha OBE, has helped build an operational structure that has grown Morningside into one of Leicestershire’s top 100 companies today.
Monica said: “I was very fortunate to start my career with Morningside and to be part of its journey, as the company has grown into one of the Midlands’ leading pharmaceuticals businesses.
“Having worked in almost every department, I am now very much looking forward to taking on an executive position to help deliver the business’ ambitious growth plans for the future. This includes continuing to introduce new products to expand our range and delivering a high quality service, while building on strong relationships with customers and suppliers.”
Cliff Fung joins Morningside as the company’s new Chief Financial Officer (CFO). He has over 25 years’ experience of working in senior finance roles within the pharmaceutical sector. He comes to Morningside from multinational pharma manufacturer and supplier Aesica Pharmaceuticals, where he was the UK Finance Director. Prior to this Cliff has worked in senior positions for PCI, Catalent and Knoll Pharma.
Cliff said: “I’m delighted to have joined Morningside Pharmaceuticals at this exciting time and I’m very much looking forward to working with my new teams, as well as the Executive Board, to take the business to the next level.
“Together with my senior managers, we plan to build on Morningside’s strengths, while overseeing and supporting the development and implementation of effective, efficient, flexible and customer focussed approaches to business support and delivery.”
Both Cliff Fung and Monica Huang started their new roles at the beginning of August 2020.